WHO ICTRP trial
A Phase III Study of atezolizumab in Combination With Carboplatin or Cisplatin +…
JPRN-jRCT2080223142 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCT2080223142 |
|---|---|
| Public title | A Phase III Study of atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed in Patients With Stage IV Non-squamous Non-small Cell Lung Cancer [IMpower132] |
| Scientific title | A PHASE III,OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB (MPDL3280A, ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN OR CISPLATIN+PEMETREXED COMPARED WITH CARBOPLATIN OR CISPLATIN+PEMETREXED IN PATIENTS WHO ARE CHEMOTHERAPY-NAIVE AND HAVE STAGE IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER |
| Primary sponsor | CHUGAI PHARMACEUTICAL CO., LTD. |
| Secondary sponsors | F. Hoffmann-La Roche Ltd |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | Asia except Japan;North America;South America;Europe;Oceania;Japan |
| Conditions | Non-Small Cell Lung Cancer |
| Interventions | investigational material(s) Generic name etc : Atezolizumab INN of investigational material : atezolizumab Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : 1200 mg intravenous… |
| Registration date | Nov 3, 2016 |
| Target size | 568 |
| Secondary IDs | NCT02657434;JapicCTI-163197 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: